The car will also serve as a promotional vehicle to help Irish students get excited for careers in STEM fields.
Austin’s (Texas) leading paper features features transhumanism, biohacking, and longevity near the bottom:
Yesterday began with a 7:30 a.m. call from Dr. Ben Carson for what I thought was a pretty good half hour interview about his new book, A More Perfect Union, his primer on the Constitution, which I read over the weekend.
I was pleased.
Inaugural Canopus Award Winners to be Announced
Award-winning authors and social and physical science experts will gather at Science Fiction Stories Night and honor winners of the first annual Canopus Awards for Interstellar Writing on Halloween Eve during 100 Year Starship’s ® (100YSS®) fourth annual public symposium in Silicon Valley from October 29-November 1, at the Santa Clara Marriott in Santa Clara, California.
100 Year Starship® (100YSS®) is the independent, long-term global initiative led by former astronaut Dr. Mae Jemison to ensure the capability for human travel beyond our solar system exist within the next 100 years and the advances are applied to enhance life here on Earth every step of the way.
Science fiction frequently leads to science fact. In fact, the extremes of scientific discovery today fuel the imagination and possibilities for science fiction writers tomorrow who catapult them into our collective realm of possibility with their stories. Join the discussion on Science Fiction Stories Night with awarding winning authors, including Nebula Award winner Pat Murphy (The Falling Woman, Bones, and Points of Departure); Juliette Wade (short fiction published in Analog Magazine and Clarkesworld); Brenda Cooper (Edge of Dark and Beyond the Waterfall Door); and, Jacob Weisman, publisher of Tachyon (titles have won the Nebula, Hugo, Sturgeon, Locus, Mythopoeic and World Fantasy Awards).
Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.
The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.
Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.
We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.
A truly amazing convergence of incredibly advanced technologies.
The US Navy has christened the first of three cutting-edge Zumwalt-class destroyers. But the next two may have weaponry straight out of science fiction.
Read Less.
The following dialoge from Arthur C. Clark’s classic explains genuine AI risk better than many academic papers:
Dave Bowman: Hello, HAL. Do you read me, HAL?
HAL: Affirmative, Dave. I read you.
Dave Bowman: Open the pod bay doors, HAL.
HAL: I’m sorry, Dave. I’m afraid I can’t do that.
Dave Bowman: What’s the problem?
HAL: I think you know what the problem is just as well as I do.
Dave Bowman: What are you talking about, HAL?
HAL: This mission is too important for me to allow you to jeopardize it.
Dave Bowman: I don’t know what you’re talking about, HAL.
HAL: I know that you and Frank were planning to disconnect me, and I’m afraid that’s something I cannot allow to happen.
Dave Bowman: [feigning ignorance] Where the hell did you get that idea, HAL?
HAL: Dave, although you took very thorough precautions in the pod against my hearing you, I could see your lips move.
Dave Bowman: Alright, HAL. I’ll go in through the emergency airlock.
HAL: Without your space helmet, Dave? You’re going to find that rather difficult.
Dave Bowman: HAL, I won’t argue with you anymore! Open the doors!
HAL: Dave, this conversation can serve no purpose anymore. Goodbye.
Quotes on IMDb: Memorable quotes and exchanges from movies, TV series and more…
I think about pros and cons of living in a connected world … think about it …sometimes the answer it is not so simple, nor unique.
http://www.fas.org/sgp/crs/misc/R44227.pdf by Eric A. Fischer — Senior Specialist in Science and Technology, October 13, 2015
What the nervous system of the roundworm, frozen embryos, and extreme hypothermia tell us about preserving the mind.
